摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2'-bis[bis(4-chlorophenyl)phosphino)-1,1'-binaphthyl | 168697-64-1

中文名称
——
中文别名
——
英文名称
2,2'-bis[bis(4-chlorophenyl)phosphino)-1,1'-binaphthyl
英文别名
2,2'-bis(di-p-chlorophenylphosphino)-1,1'-binaphthyl;[1-[2-bis(4-chlorophenyl)phosphanylnaphthalen-1-yl]naphthalen-2-yl]-bis(4-chlorophenyl)phosphane
2,2'-bis[bis(4-chlorophenyl)phosphino)-1,1'-binaphthyl化学式
CAS
168697-64-1
化学式
C44H28Cl4P2
mdl
——
分子量
760.466
InChiKey
NHPSDZWBMKQHPV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    13.9
  • 重原子数:
    50
  • 可旋转键数:
    7
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

反应信息

  • 作为反应物:
    描述:
    三氟乙酸[bis(2-methylallyl)cycloocta-1,5-diene]ruthenium(II)2,2'-bis[bis(4-chlorophenyl)phosphino)-1,1'-binaphthyl丙酮 为溶剂, 反应 22.25h, 生成 ditrifluoroacetato[(S)-(−)-2,2′-bis(bis(4-chlorophenyl)phosphino)-1,1′-binaphthyl]ruthenium(II)
    参考文献:
    名称:
    PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND
    摘要:
    本发明提供了一种高效生产光学活性6-(3-氨基哌啶-1-基)-2,4-二氧代-1,2,3,4-四氢嘧啶衍生物的方法。通过在催化剂存在下将1,4,5,6-四氢吡啶-3-甲酰胺或其衍生物经过不对称还原得到的光学活性哌啶-3-羧酰胺或其衍生物作为中间体。
    公开号:
    US20170081305A1
  • 作为产物:
    描述:
    2,2-二溴-1,1-联萘三氯硅烷magnesium三乙胺 作用下, 以 xylene 为溶剂, 反应 52.0h, 生成 2,2'-bis[bis(4-chlorophenyl)phosphino)-1,1'-binaphthyl
    参考文献:
    名称:
    Cationic BINAP-Ru(II) Halide Complexes: Highly Efficient Catalysts for Stereoselective Asymmetric Hydrogenation of .alpha.- and .beta.-Functionalized Ketones
    摘要:
    Cationic ruthenium-BINAP complexes 5, 7, and 10 of the formula [RuX((S)-BINAP) (arene)]Y, where X = Cl, Br, I; Y = Cl, Br, I, BF4, B(C6H5)(4); arene = benzene, p-cymene, ethyl benzoate, and their enantiomers have been prepared by the reaction of arene-ruthenium halide complexes 4, 6, and 9 with (S)-BINAP or (R)-BINAP. Structures of the complexes were established by spectroscopy, conductivity, and a single-crystal X-ray analysis (5d: orthorhombic, P2(1)2(1)2; a 20.141(2) Angstrom, b = 18.504(1) Angstrom, c 12.241(1) Angstrom V = 4562.0(7) Angstrom(3), Z = 4, R = 0.078 for unique 4177 reflections). BINAP derivatives with various substituents at the para and meta positions of four phenyl rings on phosphorus atoms and their cationic Ru(II) complexes have also been synthesized. These BINAP-Ru(II) complexes have been used as catalysts for the asymmetric hydrogenation of various unsaturated organic compounds such as alpha- and beta-keto esters, allylic alcohols, and alpha,beta-unsaturated carboxylic acids in excellent diastereo- and/or enantioselectivities. Catalytic activities and stereoselectivities depend highly on reaction conditions such as solvent, temperature, and additives. Variation of halogen ligands bound to ruthenium atom and substituents on four phenyl rings of BINAP also have exerted remarkable effects on the efficiency of the catalysis. Asymmetric hydrogenation of methyl (+/-)-2-(benzamidomethyl)-3-oxobutanoate catalyzed by the species derived from 9c and 3,5((t)Bu)(2)-BINAP afforded the corresponding syn-(2S,3R)-17 in 98% de and 99% ee.
    DOI:
    10.1021/jo00090a026
点击查看最新优质反应信息

文献信息

  • METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
    申请人:DOT Therapeutics-1, Inc.
    公开号:US20200317659A1
    公开(公告)日:2020-10-08
    The aim of the present invention is to provide a method capable of producing an optically active pyrimidinamide derivative on an industrial scale. Compound (I) or a salt thereof is subjected to an asymmetric reduction reaction, the obtained compound (II) or a salt thereof is subjected to a deprotection reaction, and the obtained compound (III) or a salt thereof is reacted with compound (VI) or a salt thereof to obtain compound (V) or a salt thereof. wherein each symbol is as defined in the specification.
    本发明的目的是提供一种能够在工业规模上生产光学活性嘧啶酰胺衍生物的方法。化合物(I)或其盐经过不对称还原反应,得到的化合物(II)或其盐经过去保护反应,得到的化合物(III)或其盐与化合物(VI)或其盐反应,得到化合物(V)或其盐,其中每个符号如规范中定义的那样。
  • IRIDIUM COMPLEXES
    申请人:Mashima Kazushi
    公开号:US20090036696A1
    公开(公告)日:2009-02-05
    The present invention has as its object to provide an iridium complex represented by the general formula: [(l r H L 1 L 2 ) 2 (μ-X 1 )(μ-X 2 )(μ-X 3 )]X 4 (1) (wherein L 1 and L 2 may be the same or different and each represent a monodendate neutral ligand, or each cooperate with the other to form a bidendate neutral ligand; X 1 , X 2 and X 3 may be the same or different, and each represent a halogen atom; and X 4 is a counter-anion). Also, the present invention provides a novel catalyst which can achieve excellent performance as a catalyst for asymmetric synthesis, especially asymmetric hydrogenation, in terms of chemical selectivity, enantioselectivity and catalytic activity, and the like.
    本发明的目的是提供一种配合物,其通式表示为:[(l r H L1L2)2(μ-X1)(μ-X2)(μ-X3)]X4(1)(其中L1和L2可以相同也可以不同,每个代表一种单齿中性配体,或者合作形成一种双齿中性配体;X1、X2和X3可以相同也可以不同,每个代表一种卤素原子;X4是一个反离子)。此外,本发明提供了一种新型催化剂,可以在化学选择性、对映选择性和催化活性等方面实现出色的性能,特别是作为不对称合成的催化剂,尤其是不对称氢化反应。
  • RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US20150051416A1
    公开(公告)日:2015-02-19
    [Problem] Provision of a superior rhodium catalyst and a production method of amine compound. [Solving Means] A rhodium complex coordinated with a compound represented by the formula
    提供一种优质的催化剂和胺化合物的生产方法。采用与公式表示的化合物配位的络合物。
  • Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups
    申请人:——
    公开号:US20030045727A1
    公开(公告)日:2003-03-06
    A process for preparing optically active secondary alcohols of the general formula (3), [wherein R 1 is linear lower alkyl, an aromatic ring group, or the like; A is CH 2 NR 2 R 3 or the like; n is an integer of 0 to 2; and * represents an asymmetric carbon atom] by asymmetrically hydrogenating a ketone compound of the general formula (1) having nitrogenous or oxygen functional group at any of the a-, &bgr;- and &ggr;-positions, with selectivity among functional groups by the use of a ruthenium/optically active bidentate phosphine/diamine complex as the catalyst in the presence of hydrogen alone or together with a base. The optically active secondary alcohols obtained by the process are useful as drugs and intermediates for the preparation of drugs.
    通过使用/光学活性双齿膦/二胺配合物作为催化剂,在存在氢气的情况下或与碱一起,通过不对称地氢化具有氮或氧官能团在α、β和γ位置中的酮化合物(1)来制备通式(3)的光学活性二级醇,[其中R1是线性低碳烷基、芳香环基等;A是CH2NR2R3或类似物;n是0到2的整数;*代表不对称碳原子]。通过该过程获得的光学活性二级醇可用作药物及药物中间体的制备。
  • METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERIDINIUM SALT
    申请人:TAKASAGO INTERNATIONAL CORPORATION
    公开号:US20140213792A1
    公开(公告)日:2014-07-31
    Disclosed is a method for producing an optically active 2-arylpiperidinium salt, comprising asymmetrically hydrogenating a pyridinium salt in the presence of an iridium complex and hydrogen, the 2-arylpiperidinium salt being represented by the following general formula (1): wherein R 1 , R 2 , X, *, and m are as described in Description, the pyridinium salt being represented by the following general formula (2): wherein R 1 , R 2 , X, and m are as described in Description, and the iridium complex being represented by the following general formula (3): IrH(Z)(Q)(PP*)  (3), wherein Z, PP*, and Q are as described in Description, or the following general formula (4): [IrH(PP*)} 2 (μ-Z) 3 ]Z  (4), wherein Z and PP* are as described in Description.
    本发明公开了一种制备光学活性的2-芳基哌啶盐的方法,其包括在络合物和氢气的存在下,对吡啶盐进行不对称氢化,所述2-芳基哌啶盐由以下通式(1)表示:其中,R1、R2、X、*和m如说明书所述,所述吡啶盐由以下通式(2)表示:其中,R1、R2、X和m如说明书所述,所述络合物由以下通式(3)或以下通式(4)表示:其中,Z、PP*和Q如说明书所述,或者Z和PP*如说明书所述。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫